Research Methodology used for this Study:
Top-down and bottom-up approaches were used to validate the size of the global market and estimate the size of various other dependent submarkets. Major players in the market were identified through secondary research and their market revenues were determined through primary and secondary research. Secondary sources include annual reports, press releases, and investor presentations of companies; white papers; medical journals; certified publications; articles from recognized authors; gold standard and silver standard websites; directories; and databases.
In-depth interviews were conducted with various primary respondents, which include key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as to assess future prospects.
This data is consolidated and added to detailed inputs and analysis from MarketsandMarkets and presented in this report. Some of the secondary resources referred to are World Health Organization (WHO), National Institutes of Health (NIH), National Center for Biotechnology Information (NCBI), US FDA, Parenteral Drug Association (PDA), International Society for Pharmaceutical Engineering (ISPE), and Washington Biotechnology & Biomedical Association (WBBA)
Download PDF Brochure@
Fill-finish manufacturing is the process of aseptically filling biologics in any form such as solution, powder, or suspension in containers such as vials, syringes, cartridges, ampoules, bottles, and bags. It is an integral part of biopharmaceutical manufacturing after upstream-cell culture & downstream-separation and purification operations. Key steps involved in the fill-finish process include cleaning, sterilization, filling, stoppering, lyophilization, capping, crimping, and visual inspection.
The fill-finish manufacturing market is expected to reach USD 4.47 Billion by 2022 from USD 2.96 Billion in 2017, at a CAGR of 8.6%. The base year considered for the study is 2016 and the forecast for the market size is provided for the period between 2017 and 2022.
Technological advancements in fill-finish products, growth of the biopharmaceutical industry, rising adoption of prefilled syringes, and increase in fill-finish outsourcing are the major factors driving this market.
The contract manufacturing organizations segment expected to grow at the highest rate in the next five years
On the basis of end user, the market is classified into contract manufacturing organizations, biopharmaceutical companies, and other end users. The contract manufacturing organizations segment is the fastest-growing segment in the fill-finish manufacturing market. This can primarily be attributed to the rising demand for outsourcing the fill-finish manufacturing process and growing number of new entrants in the biologics manufacturing market.
Target Audience for this Study:
# Biopharmaceutical companies
# Fill-finish product manufacturers
# Contract manufacturing companies
# Clinical research organizations
# NGOs and government organizations associated with fill-finish manufacturing
# Market research and consulting firms
Europe is expected to dominate the fill-finish manufacturing market in 2017
In 2017, Europe is expected to account for the largest share of the global fill-finish manufacturing market. The large share of the European region is mainly attributed to factors such as the emergence of biosimilar market due to patent expiry of key biologic products, rising incidence of chronic disorders, and increasing focus of major players on enhancing their presence in Europe.
Request Sample Pages@
The APAC region is expected to grow at the highest CAGR over the next five years. The growth of the fill-finish manufacturing market in this region is fueled by the overall growth in the biopharmaceutical industry.
The key players operating in this market include Becton, Dickinson and Company (US), West Pharmaceutical Services, Inc. (West Pharmaceutical Services) (US), Gerresheimer AG (Gerresheimer) (Germany), Robert Bosch GmbH (Robert Bosch) (Germany), IMA (Italy), OPTIMA (Germany), and Nipro Medical Corporation (US).
No comments:
Post a Comment